Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Emily Nizialek"'
Autor:
Srinivasan Yegnasubramanian, Emmanuel S. Antonarakis, Pedro Isaacsson Velho, Su Jin Lim, Emily Nizialek, Hao Wang
Publikováno v:
The Prostate. 81:572-579
BACKGROUND Clinical outcomes may differ among patients presenting with primary (de novo) metastatic hormone-sensitive prostate cancer (mHSPC) versus secondary (metachronous) mHSPC occurring after local therapy. It is unknown what molecular features d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4056d025e2e536f3801ec3df35405b72
https://doi.org/10.1002/pros.24135
https://doi.org/10.1002/pros.24135
Autor:
Nityam Rathi, Laura A. Sena, Neeraj Agarwal, Emmanuel S. Antonarakis, Amanda C. Larson, James R. Eshleman, Drew M. Pardoll, Pedro Isaacsson Velho, Alan H. Bryce, Benjamin L. Maughan, Colin C. Pritchard, Hao Wang, Ryan Ashkar, Su Jin Lim, Tamara L. Lotan, Julia Fountain, Roberto Nussenzveig, Nabil Adra, Miguel Gonzalez Velez, Emily Nizialek
Publikováno v:
The Oncologist
Background Genomic biomarkers that predict response to anti‐PD1 therapy in prostate cancer are needed. Frameshift mutations are predicted to generate more neoantigens than missense mutations; therefore, we hypothesized that the number or proportion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32a1ae9ad6d702cb3506561bb2761034
https://doi.org/10.1002/onco.13601
https://doi.org/10.1002/onco.13601
Publikováno v:
Cancer Management and Research
Poly (ADP-ribose) polymerase inhibitors (PARPi) are a unique class of antineoplastic agents that function by inducing synthetic lethality. Synthetic lethality occurs when PARPi and either another agent or an underlying genetic alteration together lea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::203afba0a286177408cfa0556ca29ef4
http://europepmc.org/articles/PMC7489946
http://europepmc.org/articles/PMC7489946
Publikováno v:
Cancer Management and Research. 12:8105-8114
Poly (ADP-ribose) polymerase inhibitors (PARPi) are a unique class of antineoplastic agents that function by inducing synthetic lethality. Synthetic lethality occurs when PARPi and either another agent or an underlying genetic alteration together lea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e235317127ae9029959c4ccbd89b380b
https://doi.org/10.2147/cmar.s227033
https://doi.org/10.2147/cmar.s227033
Publikováno v:
Journal of Clinical Oncology. 40:e17037-e17037
e17037 Background: The poly(ADP-ribose) polymerase inhibitors (PARPi) olaparib and rucaparib have been approved for the treatment of metastatic castration resistant prostate cancer (mCRPC) in the setting of homologous recombination deficiency (HRD).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::583d04aacfaccfde07820c8f3f17cce1
https://doi.org/10.1200/jco.2022.40.16_suppl.e17037
https://doi.org/10.1200/jco.2022.40.16_suppl.e17037
Autor:
Pauline Funchain, Ying Ni, Brandon Bungo, Brandie Heald, Michelle Arbesman, Tapas Ranjan Behera, Sarah M. Nielsen, Shelley McCormick, Jung Min Song, Emily Nizialek, Brian Gastman, Edward D. Esplin, Mykyta Artomov, Hensin Tsao, Joshua Arbesman
Publikováno v:
Journal of Clinical Oncology. 40:10523-10523
10523 Background: Melanoma has recently been suggested to be a highly heritable cancer with high twin-twin concordance. In contrast, prior studies on patients with familial atypical multiple mole melanoma (FAMMM) syndrome, multiple primary melanomas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f23014bee573e6dbbb95a25c272d2f45
https://doi.org/10.1200/jco.2022.40.16_suppl.10523
https://doi.org/10.1200/jco.2022.40.16_suppl.10523
Autor:
Jessica J. Tao, Ross C. Donehower, Rachel Karchin, Emily Nizialek, Kristen A. Marrone, Kymberleigh A. Pagel, Jenna Van Liere Canzoniero, Paola Ghanem, Valsamo Anagnostou
Publikováno v:
Journal of Clinical Oncology. 39:11035-11035
11035 Background: The accelerated impact of next generation sequencing (NGS) in clinical decision making requires the integration of cancer genomics and precision oncology focused training into medical oncology education. The Johns Hopkins Molecular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92e095494cc351474514516ab89932aa
https://doi.org/10.1200/jco.2021.39.15_suppl.11035
https://doi.org/10.1200/jco.2021.39.15_suppl.11035
Autor:
Srinivasan Yegnasubramanian, Tamara L. Lotan, Emmanuel S. Antonarakis, Channing J. Paller, Emily Nizialek, William B. Isaacs
Publikováno v:
Journal of Clinical Oncology. 39:5084-5084
5084 Background: The intersection between germline and somatic genomics is an evolving field in which germline mutations may predispose to unique patterns of subsequent somatic mutations in cancer. Germline mutations in CHEK2, involved in cell cycle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ead87c34e68ea80ccf0b0966f059c251
https://doi.org/10.1200/jco.2021.39.15_suppl.5084
https://doi.org/10.1200/jco.2021.39.15_suppl.5084
Autor:
A. Oliver Sartor, Nabil Adra, Ajjai Alva, Mary-Ellen Taplin, Heather H. Cheng, Christopher Su, Marcin Cieslik, Rahul Aggarwal, Heather McClure, Emily Nizialek, Alexandra O. Sokolova, Cora N. Sternberg, Pedro C. Barata, Panagiotis J. Vlachostergios, Ryan Ashkar, Jacob E. Berchuck, Emmanuel S. Antonarakis, Nellie Nafissi, Alan H. Bryce
Publikováno v:
Journal of Clinical Oncology. 39:5040-5040
5040 Background: PARPi have shown promise in mCRPC pts with mutations in DNA repair, but ATM- and BRCA2-altered pts may respond differently to PARPi. We hypothesized that differences may also exist for taxane therapy, aiding in treatment sequencing d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbb64566d08e5f4cba8b0232db6a199c
https://doi.org/10.1200/jco.2021.39.15_suppl.5040
https://doi.org/10.1200/jco.2021.39.15_suppl.5040
Publikováno v:
Journal of Clinical Oncology. 38:e17558-e17558
e17558 Background: Clinical outcomes may differ among pts with primary (de novo) mHSPC vs. secondary (relapsed) mHSPC occurring after previous local therapy. However, it is unknown what molecular features distinguish these potentially distinct presen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f9c781f2379e73b99e6b9e40dbb784b
https://doi.org/10.1200/jco.2020.38.15_suppl.e17558
https://doi.org/10.1200/jco.2020.38.15_suppl.e17558